Proteome Sciences (LON:PRM) Shares Down 1.9% – Should You Sell?

Proteome Sciences plc (LON:PRM)’s stock price was down 1.9% during trading on Wednesday. The stock traded as low as GBX 1.20 and last traded at GBX 1.43. 139,611 shares were traded during mid-day trading, a decline of 60% from the average daily volume of 347,772 shares. The stock had previously closed at GBX 1.46.

Proteome Sciences Stock Performance

The firm has a market cap of £5.65 million, a price-to-earnings ratio of -2.24 and a beta of 0.16. The company has a quick ratio of 0.37, a current ratio of 0.12 and a debt-to-equity ratio of -161.07. The company has a 50 day moving average of GBX 1.44 and a 200 day moving average of GBX 1.61.

Proteome Sciences (LON:PRM) last issued its quarterly earnings data on Wednesday, September 16th. The company reported GBX (0.41) earnings per share for the quarter. Proteome Sciences had a negative net margin of 61.46% and a positive return on equity of 23.85%.

Proteome Sciences Company Profile

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids.